Eckert & Ziegler Strahlen- und Medizintechnik AG / Contract
25.06.2010 11:48
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 25 June 2010. Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE0005659700) becomes the main supplier of the radioactive component
to the cancer drug ZEVALIN of the American drug company Spectrum
Pharmaceuticals Inc. (NASDAQ: SPPI), Irvine, CA. As provided by a recently
signed long-term contract, Eckert & Ziegler delivers the radioactive agent
Yttrium-90 in the US with immediate effect for the production of
ZEVALIN(R). Yttrium-90-radiolabeled ZEVALIN was approved by the US FDA in
February, 2002 for the treatment of patients with relapsed or refractory,
low grade or follicular B-cell non-Hodgkin's lymphoma and in September,
2009 was approved for an expanded label to treat patients with previously
untreated follicular non-Hodgkin's lymphoma (NHL) who achieve a partial or
complete response to first line chemotherapy.
Eckert & Ziegler's member of the Managing Board responsible for its
radio-pharmaceuticals segment, Dr. André HeÃ, said: 'We are glad to have
been chosen by Spectrum Pharmaceuticals as the main supplier to this
interesting product. The decisive factor, besides the high product quality
of our Yttrium-90 was our flexible delivery capability that enables product
delivery every weekday. For years we have produced Yttrium-90 of
pharmaceutical quality in our production site in Braunschweig, Germany and
have established an excellent reputation with our customers on various
continents. As the demand grows we will also invest in new production
facilities in the core markets.'
Eckert & Ziegler operates a number of production sites for
radio-pharmaceuticals in Europe and, besides Fluor-18-based
radio-diagnostic products for nuclear-medical imaging (PET), also markets
its Yttrium-90 in Europe as the EMEA approved product 'Yttriga', a
precursor product of numerous radio-therapeutic products. It is, among
other things, being used for the treatment of liver cancer. Eckert &
Ziegler also provides synthesis technology and -Gallium-68-(PET)
radio-nuclide generators for nuclear medical facilities worldwide.
Spectrum Pharmaceutical's Chairman, Chief Executive Officer, and President,
Rajesh C. Shrotriya, MD, said: 'The framework contract with Eckert &
Ziegler further safeguards and enhances our supply chain to ZEVALIN for the
radioactive isotope Yttrium-90. We will now be able to supply and
administer ZEVALIN to patients 6 days a week, rather than the previous
availability of only 2 days per week. The recent FDA approval for ZEVALIN
in the 1st line setting has resulted in continued optimism on ZEVALIN's
growth prospects. ZEVALIN has received a Category 1 recommendation from the
National Comprehensive Cancer Network(R) Drugs and Biologic Compendium(TM)
and we have expanded our sales force and are making progress toward a
streamlined reimbursement standard in both the hospital and community
setting for this important therapeutic.'
About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG is a global isotope
technology company and holding company for a number of specialized
subsidiary companies in the field of processing of radioisotopes and of
development, production, and marketing of isotope technology components,
medical devices, and similar products. A public company listed as 'EUZ' on
the Deutsche Börse the group generated a turnover of EUR 101 million in
2009 and is one of the largest suppliers of radioactive components for
radiation therapy and nuclear medicine, employing 520 employees worldwide.
Please visit our Website at www.ezag.com for more information on Eckert &
Ziegler.
About ZEVALIN(R) and the ZEVALIN(R) Therapeutic Regimen
ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients
with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who
achieve a partial or complete response to first-line chemotherapy. ZEVALIN
is also indicated for the treatment of patients with relapsed or
refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.
ZEVALIN is a CD20-directed radiotherapeutic antibody. The ZEVALIN
therapeutic regimen consists of three components: rituximab, Indium-111
(In-111) radiolabeled ZEVALIN for imaging, and Yttrium-90 (Y-90)
radiolabeled ZEVALIN for therapy. The ZEVALIN therapeutic regimen is a form
of cancer therapy called radioimmunotherapy. Radioimmunotherapy (RIT) is an
innovative form of cancer treatment with a mechanism of action that is
different from traditional chemotherapy. RIT builds on the combined effect
of a targeted biologic monoclonal antibody augmented with the therapeutic
effects of a beta-emitting radioisotope. Full prescribing information can
be found at www.zevalin.com.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a
focus in oncology and hematology. The Company's strategy is comprised of
acquiring, developing and commercializing a broad and diverse pipeline of
late-stage clinical and commercial products. In addition to continuing to
build an efficient in-house clinical research organization with regulatory
and data management capabilities, the Company has established a commercial
infrastructure to market its drug portfolio. The Company markets two
oncology drugs, ZEVALIN(R) and FUSILEV(R) and has two drugs in late stage
development, apaziquone and belinostat, along with a diverse pipeline. The
Company also leverages the expertise of its worldwide partners to assist in
the execution of its strategy. For more information, please visit the
Company's website at www.sppirx.com.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin, Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-Mail:
karolin.riehle@ezag.de, www.ezag.com
25.06.2010 11:48 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Eckert & Ziegler Becomes Main Supplier to Innovative Leukaemia Drug
| Source: EQS Group AG